^
    Back
    Association details:
    Biomarker:CD19 positive
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:puzolcabtagene autoleucel (pCAR-19B) (CD19-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Safety and tolerability study of MC-1-50 cell preparation in CD19-positive R/R B-ALL

    Excerpt:
    ......
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Safety and tolerability studies of pCAR-19B in CD19-positive R/R B-ALL

    Excerpt:
    ......
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+ B-ALL

    Published date:
    11/03/2022
    Excerpt:
    As of June 30, 2022, nine patients (3 in DL1, 6 in DL2) were infused with pCAR-19B and all patients have finished at least 6 months follow up visit. Demographics, baseline disease, prior treatment and special concerned adverse events are presented in the table...pCAR-19B has demonstrated a good safe profile and 100% CR rate in phase I study for adults R/R CD19+ B-ALL.
    DOI:
    https://doi.org/10.1182/blood-2022-162134
    Trial ID:
    NCT04888442